NorthStrive and Yuva Biosciences validate four ANT1-inducing compounds
NorthStrive Biosciences, a subsidiary of NASDAQ-listed PMGC Holdings, has reported positive results from Phase III of its AI-driven drug discovery collaboration with Yuva Biosciences. Four small-molecule candidates selected by Yuva's proprietary MitoNova platform demonstrated statistically significant induction of ANT1, a mitochondrial protein involved in energy metabolism in skeletal muscle, when tested in primary human skeletal muscle cells.
The strongest increases in ANT1 expression were observed for compound C2, at up to 50%, followed by C4 at up to 48% and C1 at up to 46%. A fourth candidate, C3, achieved a 29% increase at the highest tested dose and was also advanced on the basis of statistically significant activity. Three of the four compounds, C1, C2 and C4, were described by Yuva Biosciences as the most dose-consistent inducers.
What the results mean
The Phase III study was an in vitro validation step, not a clinical trial. Compounds were evaluated using an assay measuring ANT1 protein expression in primary human cells, a relatively early-stage method for confirming that AI-generated predictions have measurable biological effect. The positive findings clear the way for what Yuva Biosciences has described as a more mature, energy-demanding skeletal muscle model, designed to assess whether the ANT1 induction holds in conditions more representative of adult muscle biology.
NorthStrive's broader development strategy centres on muscle preservation in the context of weight-loss treatments, including GLP-1 receptor agonist therapies. Its lead asset, EL-22, is an engineered probiotic candidate targeting the same clinical problem. The company has not disclosed a timeline for progressing any of the four validated compounds into animal studies or IND-enabling work.
Market and competitive context
The muscle-preservation space has attracted growing attention as the rapid commercial uptake of GLP-1 agonists such as semaglutide and tirzepatide raises questions about lean muscle loss alongside fat reduction. Several early-stage companies and academic groups are exploring pharmacological approaches to protect muscle mass during weight loss, including myostatin inhibitors, selective androgen receptor modulators, and mitochondria-targeted compounds. NorthStrive is pursuing a relatively differentiated angle by combining an AI-driven small-molecule discovery platform with a probiotic lead asset, though both programmes remain at preclinical stages.
The use of AI platforms for early compound selection is now well-established across the sector, with a range of companies applying machine learning to target identification and candidate screening. What distinguishes programmes at this stage is the quality of downstream biological validation and the speed with which promising in vitro hits can be de-risked in more complex models. MitoNova's sixth-generation classifier models were cited in NorthStrive's prior update as an improvement on earlier iterations, though the company has not published comparative performance data.
Investors will want clarity on the next stage timeline and on which, if any, of the four compounds is designated as a lead. The absence of named development milestones and the preliminary nature of the in vitro data mean the programme is at an early juncture, and significant work remains before any clinical application can be assessed.